Did GTXI mgmt only release a abridged version of the clinical study and why only a few months ago, years after conclusion, the full study was release. well the last question is probably a clue. The law permitted non release of clinical data, however if SARM fail in phase III, and mgmt did not release all data prior to, then the lawsuits will begin. a jury can concluded material data was witheld, by release full data, investors "take your won risk". Smart, but AF was correct, must likely this drug was a bomb, which merck knows all along.
That was a copy and paste from a poster who obviously is not blinded by all the longs posting who where blinders.
GTXI cash burn rate and bad results will be a double slam to those left holding the bag.